Phio Pharmaceuticals (PHIO) Cash from Operations (2011 - 2026)

Phio Pharmaceuticals (PHIO) has reported Cash from Operations for 16 consecutive years, with -$4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 58.86% year-over-year to -$4.0 million; the trailing twelve-month figure through Jun 2026 stood at -$12.2 million (down 70.92% YoY), and the FY2025 full-year result was -$8.0 million, down 12.19% from the prior year.
• Cash from Operations eased to -$4.0 million in Q2 2026 per PHIO's latest filing, from -$4.0 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$1.3 million in Q1 2025 and bottomed at -$4.0 million in Q2 2026.
• Historically, Cash from Operations has averaged -$2.6 million across 5 years, with a median of -$2.5 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash from Operations soared 42.15% in 2024, then slumped 213.96% in 2026.
• Over 5 years, Cash from Operations stood at -$2.7 million in 2022, then advanced by 12.38% to -$2.4 million in 2023, then jumped by 42.15% to -$1.4 million in 2024, then slumped by 51.64% to -$2.1 million in 2025, then plunged by 94.08% to -$4.0 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$4.0 million, -$4.0 million, and -$2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.